Tinidazole

證據等級: L5

預測適應症: 10 個

Tinidazole: From Antiprotozoal/Antimicrobial Infection to Postmenopausal Atrophic Vaginitis

One-Sentence Summary

Tinidazole is a 5-nitroimidazole antimicrobial agent, pharmacologically known for treating anaerobic bacterial and protozoal infections (e.g., trichomoniasis, giardiasis, amebiasis), though no TFDA-approved indication record exists in this evidence pack. The TxGNN model predicts it may be effective for Postmenopausal Atrophic Vaginitis, with a very high similarity score, but currently no clinical trials or published literature support this specific prediction. The evidence level is the lowest tier (L5 — model prediction only), and the drug’s own repurposing rationale flags this as a likely knowledge-graph co-occurrence artifact rather than a genuine pharmacological relationship.

Quick Overview

Item	Content
Original Indication	Not available in TFDA licensing records (drug is not marketed in Taiwan). Based on general pharmacological classification, tinidazole is a 5-nitroimidazole used for anaerobic bacterial/protozoal infections (trichomoniasis, giardiasis, amebiasis)
Predicted New Indication	Postmenopausal Atrophic Vaginitis
TxGNN Prediction Score	99.93%
Evidence Level	L5
US Market Status	Not Marketed (未上市)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for tinidazole is not available (data gap). Based on general pharmacological knowledge, tinidazole is a 5-nitroimidazole prodrug that, once activated by the ferredoxin-reduction system in anaerobic bacteria and protozoa, generates cytotoxic free radicals that damage microbial DNA. It is active against Trichomonas vaginalis, Giardia, and Entamoeba histolytica.

Postmenopausal atrophic vaginitis, however, is primarily caused by estrogen deficiency after menopause, leading to vaginal mucosal thinning and reduced lubrication — a non-infectious, hormone-driven pathology. Tinidazole has no known estrogenic, mucosal-repair, or hormonal activity, and its antimicrobial mechanism does not directly address this underlying cause.

Assessment provided in the evidence pack itself explicitly flags this as a low-confidence prediction: the high TxGNN score likely reflects knowledge-graph node co-occurrence (e.g., “vaginal disease” nodes linked to “antibiotic treatment for vaginal infection” edges) rather than a true pharmacological relationship. No clinical trials or literature currently exist to support tinidazole’s use in postmenopausal atrophic vaginitis. This prediction should be treated as a hypothesis-generating signal only, not a basis for further clinical development at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

No approved drug licenses are currently recorded for tinidazole in this jurisdiction (taiwan_regulatory.total_licenses = 0, market status: 未上市 / Not Marketed). No product-level marketing data is available for review.

Safety Considerations

Please refer to the package insert for safety information.

(All safety fields — key warnings, contraindications, and drug-drug interactions — are currently data gaps in this evidence pack. Notably, DG001 flags TFDA package insert warnings/contraindications as a Blocking data gap that must be resolved before any safety pre-screening (S1) can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale:

The TxGNN score for postmenopausal atrophic vaginitis is high (99.93%), but this is unsupported by any clinical trial or literature evidence (L5), and the evidence pack’s own mechanistic analysis suggests the prediction is likely a knowledge-graph artifact rather than a real pharmacological signal. There is no biologically coherent link between tinidazole’s antimicrobial mechanism and estrogen-deficiency-driven mucosal atrophy.

To proceed, the following is needed:

TFDA package insert data (warnings/contraindications) — currently a Blocking data gap (DG001) that prevents even preliminary safety screening
Confirmed mechanism of action (MOA) data (DG002)
If this indication is to be pursued further, dedicated mechanistic or preclinical studies specifically linking tinidazole to vaginal mucosal/estrogen pathways would be required, as none currently exist

Note on alternative candidates: Among the 10 TxGNN-predicted indications in this evidence pack, rank 5 (AIDS) stands out with meaningfully stronger evidence — L3 evidence level, 1 supporting clinical trial (NCT03412071, microbiome-focused HIV susceptibility intervention), and 16 literature references, mostly relating to tinidazole’s established role in treating anaerobic/protozoal co-infections (e.g., trichomoniasis, amebiasis) in HIV/AIDS populations. This indication may represent a more promising “Research Question”-stage candidate than the top-ranked prediction and could warrant a separate, dedicated evaluation report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.